Equity Profile

TVTX

Travere Therapeutics, Inc.

Health CareBiotechnology$5.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, especially after recent positive surprises.

N/A

Revenue Growth

Revenue growth will help assess the company's ability to expand its market presence and support future profitability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $5 billion, it plays a crucial role in addressing unmet medical needs in the healthcare sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations of a loss. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing rare diseases with innovative therapies.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Travere's upcoming earnings report, given its recent strong performance.

Bull Case

If the company continues to beat EPS expectations and shows solid revenue growth, it could signal strong momentum and further investor confidence.

Bear Case

Conversely, any signs of slowing growth or missed expectations could lead to a significant decline in stock price, given the high market cap.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's recent track record of beating EPS estimates, this will be a key indicator of ongoing performance.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is critical for sustaining investor confidence and supporting the company's valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Travere to exceed EPS expectations again, given its recent strong performance.

Supporting Evidence

The company has consistently surprised on the upside in recent quarters, indicating strong operational execution.

Options pricing suggests a significant move, which may reflect underlying bullish sentiment not fully captured by consensus.

Key Risk

If EPS comes in below $0.00, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to maintain profitability and grow revenue amidst a competitive landscape.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, showcasing continued profitability.

Bear Confirmed If

An EPS below $0.00 would confirm the bear case, indicating potential challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests a potential stock increase of around 0.68%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 2.16%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future earnings and revenue expectations.
5Responses to analyst questions regarding recent performance trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, especially after recent positive surprises.

N/A

Revenue Growth

Revenue growth will help assess the company's ability to expand its market presence and support future profitability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations of a loss. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing rare diseases with innovative therapies.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Travere's upcoming earnings report, given its recent strong performance.

Bull Case

If the company continues to beat EPS expectations and shows solid revenue growth, it could signal strong momentum and further investor confidence.

Bear Case

Conversely, any signs of slowing growth or missed expectations could lead to a significant decline in stock price, given the high market cap.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's recent track record of beating EPS estimates, this will be a key indicator of ongoing performance.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is critical for sustaining investor confidence and supporting the company's valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Travere to exceed EPS expectations again, given its recent strong performance.

Supporting Evidence

The company has consistently surprised on the upside in recent quarters, indicating strong operational execution.

Options pricing suggests a significant move, which may reflect underlying bullish sentiment not fully captured by consensus.

Key Risk

If EPS comes in below $0.00, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to maintain profitability and grow revenue amidst a competitive landscape.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, showcasing continued profitability.

Bear Confirmed If

An EPS below $0.00 would confirm the bear case, indicating potential challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests a potential stock increase of around 0.68%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 2.16%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future earnings and revenue expectations.
5Responses to analyst questions regarding recent performance trends.